Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605).
T. Hirashima
No relevant relationships to disclose
I. Okamoto
Honoraria - Chugai Pharma; Lilly
H. Yoshioka
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
M. Ando
No relevant relationships to disclose
K. Takeda
No relevant relationships to disclose
T. Seto
No relevant relationships to disclose
N. Yamamoto
No relevant relationships to disclose
H. Saka
No relevant relationships to disclose
K. Asami
No relevant relationships to disclose
S. Kudoh
No relevant relationships to disclose
M. Satouchi
Honoraria - AstraZeneca; Chugai Pharma
N. Ikeda
No relevant relationships to disclose
Y. Iwamoto
No relevant relationships to disclose
T. Sawa
No relevant relationships to disclose
M. Miyazaki
No relevant relationships to disclose
K. Tamura
No relevant relationships to disclose
T. Kurata
Consultant or Advisory Role - Takeda (U)
Honoraria - AstraZeneca; Lilly
M. Fukuoka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo
K. Nakagawa
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical